Journal of Thyroid Cancer invites high quality submissions that advance thyroid cancer diagnosis, treatment, and survivorship care. We welcome original research, systematic reviews, clinical trials, and translational studies that improve outcomes for patients with thyroid malignancies.

Our editorial focus prioritizes rigorous study design, transparent reporting, and actionable insights for endocrine oncology practice.

• Papillary, follicular, medullary, and anaplastic thyroid carcinoma
• Molecular diagnostics, mutation profiling, and risk stratification
• Ultrasound, imaging, and thyroid nodule evaluation
• Fine needle aspiration cytology and Bethesda classification
• Surgical oncology and lymph node management
• Radioactive iodine therapy and response assessment
• Targeted therapies, immunotherapy, and systemic treatments
• Endocrine outcomes, TSH suppression, and long term follow up
• Recurrence surveillance and biomarkers such as thyroglobulin
• Quality of life, survivorship, and patient reported outcomes
• Clinical guidelines, policy updates, and multidisciplinary care
• Pediatric and hereditary thyroid cancer syndromes

• Clinical trial reports and interim analyses
• Case series with rigorous diagnostic criteria
• Practice or policy briefs grounded in evidence
• Technical notes on surgical or imaging methods

Successful submissions present a clear clinical question, robust diagnostic methodology, and transparent reporting of outcomes. We value studies that connect molecular or imaging findings to clinical decision making.

Authors should document staging, risk stratification, and treatment protocols to support reproducibility and guideline relevance.

• Clear inclusion and exclusion criteria with staging detail
• Validated biomarkers or imaging criteria
• Appropriate statistical analysis and confounder control
• Interpretation aligned with clinical practice implications

Submissions undergo editorial screening for scope fit, methodological rigor, and reporting completeness. Qualified manuscripts move to single blind peer review with subject matter experts.

JTC operates under an open access model to ensure thyroid cancer evidence is discoverable and reusable. APCs are applied after acceptance and support peer review, production, and archiving services.

Membership options and affordable APC waivers are available for eligible authors. Contact the editorial office at [email protected] for guidance.

JTC is committed to rigorous, transparent publishing in thyroid cancer research and care. We emphasize reproducible clinical methods, clear reporting of diagnostic criteria, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in endocrine oncology, surgical outcomes, and translational thyroid research.